Nov 15, 2021 4:01pm EST Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 12, 2021 8:00am EST Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Nov 11, 2021 6:00am EST Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
Oct 18, 2021 4:01pm EDT Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
Sep 27, 2021 4:01pm EDT Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Sep 21, 2021 8:00am EDT Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Sep 01, 2021 6:00am EDT Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
Aug 17, 2021 5:45pm EDT Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
Aug 12, 2021 7:21pm EDT Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
Mar 30, 2021 8:00am EDT Dermata Therapeutics Announces Initiation of a Phase 1b Trial of the Once-Weekly Topical Application of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
